5/9/2013

The FDA has widened the fast-track status for Cubist Pharmaceuticals' CXA-201 drug to include hospital-acquired bacterial pneumonia and complicated urinary tract infections. The therapy targets pathogens including multidrug resistant Pseudomonas aeruginosa.

Full Story:
Boston Herald

Related Summaries